HIV InfectionsPhase 3NCT07682961
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
A Phase 3 study testing Lenacapavir, Lenacapavir Tablet and Teropavimab in people with HIV Infections, run by Gilead Sciences at 19 sites in 3 countries.
Trial summary
The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment, after 1 year (52… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- HIV Infections
- What is being tested?
- Lenacapavir, Lenacapavir Tablet and Teropavimab
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 590 participants
- Where
- 19 sitesin 3 countries
- Study dates
- 14 Jul 2026to Mar 2033
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Human immunodeficiency virus type 1 (HIV-1) susceptibility results from screening meeting specific criteria:
- 1) Proviral phenotypic susceptibility to both TAB and ZAB by the investigational protocol-defined assay at screening.
- At least 1 documented HIV-1 RNA level measured between 6 months and 12 months (+2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL). A single virologic elevation of ≥ 50 copies/mL and < 400 copies/mL (transient detectable viremia or "blips") prior to screening are acceptable if the subsequent plasma HIV-1 RNA level is < 50 copies/mL.
- A plasma HIV-1 RNA test < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL) within the last 6 months prior to screening.
- 1) If > 1 plasma HIV-1 RNA measurements in the last 6 months prior to screening are available, all must be < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
- On a stable oral ARV therapy (ART) for ≥ 6 months prior to screening.
- A change in ART regimen ≥ 3 months prior to the screening visit for reasons other than virologic failure (VF) (eg, tolerability, simplification, drug-drug interaction profile) is allowed; individuals with a change in ART regimen ≥ 3 months prior to screening must have been on the regimen for ≥ 3 months prior to screening, and all HIV-1 RNA measurements in that period must be < 50 copies/mL. There are no permitted changes to ART regimens between screening and Day 1.
Who cannot join
- History of an opportunistic infection or illness indicative of Stage 3 HIV disease.
- History of treatment failure.
- Known or suspected resistance to either CAB or RPV.
- Resistance to CAB defined as the following mutations: G118R, Q148K, Q148R, T66K+L74M, E92Q+N155H, E138A+Q148R, E138K+Q148K/R, G140C+Q148R, G140S+Q148H/K/R, Y143H+N155H, and Q148R+N155H.
- Resistance to RPV defined as the following mutations: K101E and P; E138A, G, K, R, and Q; V179L; Y181C, I, and V; Y188L; H221Y; F227C; M230I and L, and the combination of L100I/K103N.
- Individuals with a dermatologic condition or implanted prothesis overlying the gluteal injection site for CAB + RPV.
Show all 30Show fewer
- Known hypersensitivity to the study intervention, its metabolites, or formulation excipients.
- Active, serious infections (other than HIV-1) requiring therapy < 30 days prior to randomization.
- Active tuberculosis infection.
- Acute hepatitis of any cause < 30 days before randomization.
- History of, or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, or variceal bleeding) or severe hepatic impairment (Child-Pugh Class C).
- Active malignancy requiring acute systemic therapy.
- Have poor venous access that would limit phlebotomy or intravenous (IV) infusion of study drugs.
- Prior use of, or exposure to, LEN or a broadly neutralizing antibody (bNAb) for HIV-1.
- Prior use of, or exposure to, long-acting (LA) injectable CAB or LA injectable RPV.
- Prior use of, or exposure to, ibalizumab, fostemsavir, or maraviroc.
- Baseline regimen consisting of monotherapy with any single antiretroviral (ARV).
- Treatment with immunosuppressant therapies (eg, corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies) within 4 weeks of screening (with the exception of a single short course of corticosteroids lasting ≤ 7 days) or have a comorbid condition with an anticipated need ongoing immunosuppressive treatment during the study.
- Hepatitis C virus (HCV) antibody positive and HCV RNA detectable.
- Chronic hepatitis B virus (HBV) infection, as determined by either:
- Positive HBV surface antigen and negative HBV surface antibody, regardless of HBV core antibody status, at the screening visit.
- Positive HBV core antibody and negative HBV surface antibody, regardless of HBV surface antigen status, at the screening visit.
- Severe renal impairment-estimated glomerular filtration rate < 30 mL/min according to the Cockcroft-Gault formula.
- Abnormal electrocardiogram (ECG) at the screening visit that is clinically significant, as determined by the investigator.
- Any of the following laboratory values at screening:
- Alanine aminotransferase > 5 x upper limit of normal (ULN).
- Direct bilirubin > 1.5 x ULN.
- Platelets < 50,000/mm^3.
- Hemoglobin < 8.0 g/dL.
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Trial locations and contacts
19 sites in 3 countries. Contact the study team or a site near you to ask about taking part.
Gilead Clinical Study Information Center contact
19 sites in 3 countries
United States16 sites, 16 recruiting
- Recruiting
Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID)
Annandale, Virginia, 22003
- Recruiting
Atlanta ID Group, PC
Atlanta, Georgia, 30309
- Recruiting
Be Well Medical Center
Berkley, Michigan, 48072
- Recruiting
North Texas Infectious Diseases Consultants, P.A.
Dallas, Texas, 75246
- Recruiting
Midland Florida Clinical Research Center, LLC
DeLand, Florida, 32720
- Recruiting
CAN Community Health Fort Lauderdale
Fort Lauderdale, Florida, 33316
- Recruiting
Midway Immunology and Research Center
Ft. Pierce, Florida, 34982
- Recruiting
KC CARE Health Center
Kansas City, Missouri, 64111
- Recruiting
CAN Community Health Miami Gardens
Miami Gardens, Florida, 33055
- Recruiting
BLISS Health Inc.
Orlando, Florida, 32803
- Recruiting
Optimus Medical Group
San Francisco, California, 94102
- Recruiting
Chatham County Health Department
Savannah, Georgia, 31401
- Recruiting
TribalMed PLLC
Seattle, Washington, 98104
- Recruiting
MOORE Clinical Research, Inc d/b/a TrueBlue Clinical Research
Tampa, Florida, 33614
- Recruiting
Triple O Research Institute, P.A.
West Palm Beach, Florida, 33407
- Recruiting
Atlantic Clinical Research Institute
West Palm Beach, Florida, 33409
Australia2 sites, 2 recruiting
- Recruiting
Taylor Square Private Clinic
Surry Hills, New South Wales, 2010
- Recruiting
East Sydney Doctors
Sydney, New South Wales, 2010
Japan1 site, 1 recruiting
- Recruiting
National Hospital Organization Osaka National Hospital
Osaka, 540-0006
About this study
Official title: A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment, after 1 year (52 weeks) of the treatment.
The primary objective of this study are to evaluate the efficacy of switching to the regimen of LEN, TAB, and ZAB versus switching to CAB and RPV in virologically suppressed people with HIV-1 (PWH) as determined by the proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52.
- Conditions
- HIV Infections
- Being tested
- Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir
- Medical subject headings
- HIV Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LenacapavirDrug
Also called LEN
Administered subcutaneously
Lenacapavir TabletDrug
Also called LEN
Administered orally
TeropavimabDrug
Also called TAB, GS-5423
Administered intravenously (IV)
ZinlirvimabDrug
Also called ZAB, GS-2872
Administered IV
CabotegravirDrug
Also called CAB
Administered intramuscular (IM)
RilpivirineDrug
Also called RPV
Administered IM
| Study group | Role | What they receive |
|---|---|---|
| Treatment Group 1: Lenacapavir(LEN)+ Teropavimab(TAB)+ Zinlirvimab (ZAB) | Experimental | Participants will receive oral LEN 600 mg, subcutaneous (SC) LEN 927 mg, and intravenously (IV) infusions of TAB and ZAB on Day 1. Participants will self-administer oral LEN 600 mg on Day 2. Every 26 weeks, participants will receive SC LEN and IV infusions of TAB and ZAB up to Week 92.
After Week 92, eligible participants will have an option to continue LEN + TAB + ZAB in the extension phase, until completion of the extension phase, permanently discontinuing the extension phase or the extension is discontinued at the sponsor's sole discretion, whichever occurs first. Receives: Drug: Lenacapavir; Drug: Lenacapavir Tablet; Drug: Teropavimab; Drug: Zinlirvimab |
| Treatment Group 2: Cabotegravir (CAB) + Rilpivirine (RPV) | Active comparator | Participants will discontinue their baseline oral antiretroviral therapy (ART) and will receive intramuscular (IM) CAB 600 mg + RPV 900 mg on Day 1, Week 4 and then every 8 weeks for up to 92 weeks.
After Week 92, eligible participants will have an option to continue LEN + TAB + ZAB in the extension phase, until completion of the extension phase, permanently discounting the extension phase or the extension is discontinued at the sponsor's sole discretion, whichever occurs first. Receives: Drug: Cabotegravir; Drug: Rilpivirine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Participants With HIV-1 ribonucleic acid (RNA) ≥ 50 Copies/mL at Week 52 as Defined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm.
Measured: Week 52
Secondary outcomes (12)
Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 92 as Defined by the US FDA Snapshot Algorithm.
Measured: Week 92
Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm
Measured: Week 52
Proportion of Participants with HIV-1 RNA < 50 copies/mL at Week 92 as Determined by the US FDA Snapshot Algorithm.
Measured: Week 92
Change From Baseline in clusters of differentiation 4 (CD4) (CD4)+ T-cell Counts at Week 52
Measured: Baseline, Week 52
Change From Baseline in CD4+ T-cell Counts at Week 92
Measured: Baseline, Week 92
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)
Measured: Up to Week 92
Percentages of Participants Prematurely Discontinuing Their Study Treatment due to an AE
Measured: Up to Week 92
Trough Concentrations for LEN, TAB, and ZAB at Week 26
Measured: Week 26
Trough Concentrations for LEN, TAB, and ZAB at Week 52
Measured: Week 52
Trough Concentrations for LEN, TAB, and ZAB at Week 104
Measured: Week 104
Percentages of Participants With Antidrug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) of TAB
Measured: Up to 92 Weeks
Percentages of Participants With of ADAs and NAbs of ZAB
Measured: Up to 92 Weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2026
- Study start14 Jul 2026
- Primary completionMar 2029 (estimated)
- Study completionMar 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV InfectionsStudies of the same condition, open and under way.
- More trials run by Gilead SciencesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 590 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Gilead Sciences
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Gilead Study Director, Study director, Gilead Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07682961
- Sponsor's protocol ID
- GS-US-536-5938
- Other IDs
- 2025-524335-39, 2025
- Status last verified
- Aug 2026
- First submitted
- 26 Jun 2026
- Last updated
- 14 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
- ClinicalTrials.gov ID
- NCT07682961
- Acronym / sponsor ID
- GS-US-536-5938
- Conditions
- HIV Infections
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 590 participants (estimated)
- Lead sponsor
- Gilead SciencesIndustry (pharma, biotech, devices)
- Study start
- 14 Jul 2026 (actual)
- Primary completion
- Mar 2029 (estimated)
- Study completion
- Mar 2033 (estimated)
- First posted
- 6 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment, after 1 year (52 weeks) of the treatment.
The primary objective of this study are to evaluate the efficacy of switching to the regimen of LEN, TAB, and ZAB versus switching to CAB and RPV in virologically suppressed people with HIV-1 (PWH) as determined by the proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 52.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment Group 1: Lenacapavir(LEN)+ Teropavimab(TAB)+ Zinlirvimab (ZAB) | Experimental | Drug: Lenacapavir, Drug: Lenacapavir Tablet, Drug: Teropavimab, Drug: ZinlirvimabParticipants will receive oral LEN 600 mg, subcutaneous (SC) LEN 927 mg, and intravenously (IV) infusions of TAB and ZAB on Day 1. Participants will self-administer oral LEN 600 mg on Day 2. Every 26 weeks, participants will receive SC LEN and IV infusions of TAB and ZAB up to Week 92. After Week 92, eligible participants will have an option to continue LEN + TAB + ZAB in the extension phase, until completion of the extension phase, permanently discontinuing the extension phase or the extension is discontinued at the sponsor's sole discretion, whichever occurs first. |
| Treatment Group 2: Cabotegravir (CAB) + Rilpivirine (RPV) | Active comparator | Drug: Cabotegravir, Drug: RilpivirineParticipants will discontinue their baseline oral antiretroviral therapy (ART) and will receive intramuscular (IM) CAB 600 mg + RPV 900 mg on Day 1, Week 4 and then every 8 weeks for up to 92 weeks. After Week 92, eligible participants will have an option to continue LEN + TAB + ZAB in the extension phase, until completion of the extension phase, permanently discounting the extension phase or the extension is discontinued at the sponsor's sole discretion, whichever occurs first. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Human immunodeficiency virus type 1 (HIV-1) susceptibility results from screening meeting specific criteria:
- 1) Proviral phenotypic susceptibility to both TAB and ZAB by the investigational protocol-defined assay at screening.
- At least 1 documented HIV-1 RNA level measured between 6 months and 12 months (+2 months) prior to screening. This and any other HIV-1 RNA measurements documented in this period must be < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL). A single virologic elevation of ≥ 50 copies/mL and < 400 copies/mL (transient detectable viremia or "blips") prior to screening are acceptable if the subsequent plasma HIV-1 RNA level is < 50 copies/mL.
- A plasma HIV-1 RNA test < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL) within the last 6 months prior to screening.
- 1) If > 1 plasma HIV-1 RNA measurements in the last 6 months prior to screening are available, all must be < 50 copies/mL (undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
Key exclusion criteria (30 listed)
- History of an opportunistic infection or illness indicative of Stage 3 HIV disease.
- History of treatment failure.
- Known or suspected resistance to either CAB or RPV.
- Individuals with a dermatologic condition or implanted prothesis overlying the gluteal injection site for CAB + RPV.
- Known hypersensitivity to the study intervention, its metabolites, or formulation excipients.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LenacapavirAlso: LENAdministered subcutaneously | Drug | Treatment Group 1: Lenacapavir(LEN)+ Teropavimab(TAB)+ Zinlirvimab (ZAB) |
| Lenacapavir TabletAlso: LENAdministered orally | Drug | Treatment Group 1: Lenacapavir(LEN)+ Teropavimab(TAB)+ Zinlirvimab (ZAB) |
| TeropavimabAlso: TAB, GS-5423Administered intravenously (IV) | Drug | Treatment Group 1: Lenacapavir(LEN)+ Teropavimab(TAB)+ Zinlirvimab (ZAB) |
| ZinlirvimabAlso: ZAB, GS-2872Administered IV | Drug | Treatment Group 1: Lenacapavir(LEN)+ Teropavimab(TAB)+ Zinlirvimab (ZAB) |
| CabotegravirAlso: CABAdministered intramuscular (IM) | Drug | Treatment Group 2: Cabotegravir (CAB) + Rilpivirine (RPV) |
| RilpivirineAlso: RPVAdministered IM | Drug | Treatment Group 2: Cabotegravir (CAB) + Rilpivirine (RPV) |
Primary outcome
Proportion of Participants With HIV-1 ribonucleic acid (RNA) ≥ 50 Copies/mL at Week 52 as Defined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm.
Time frame: Week 52
12 secondary outcomes
Proportion of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 92 as Defined by the US FDA Snapshot Algorithm.
Time frame: Week 92
Proportion of Participants With HIV-1 RNA < 50 Copies/mL at Week 52 as Determined by the US FDA Snapshot Algorithm
Time frame: Week 52
Proportion of Participants with HIV-1 RNA < 50 copies/mL at Week 92 as Determined by the US FDA Snapshot Algorithm.
Time frame: Week 92
Change From Baseline in clusters of differentiation 4 (CD4) (CD4)+ T-cell Counts at Week 52
Time frame: Baseline, Week 52
Change From Baseline in CD4+ T-cell Counts at Week 92
Time frame: Baseline, Week 92
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)
Time frame: Up to Week 92
Percentages of Participants Prematurely Discontinuing Their Study Treatment due to an AE
Time frame: Up to Week 92
Trough Concentrations for LEN, TAB, and ZAB at Week 26
Time frame: Week 26
Trough Concentrations for LEN, TAB, and ZAB at Week 52
Time frame: Week 52
Trough Concentrations for LEN, TAB, and ZAB at Week 104
Time frame: Week 104
Percentages of Participants With Antidrug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) of TAB
Time frame: Up to 92 Weeks
Percentages of Participants With of ADAs and NAbs of ZAB
Time frame: Up to 92 Weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Gilead Clinical Trials WebsiteLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for HIV Infections
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Gilead Clinical Study Information Center contact
Gilead Study Director study director
Gilead Sciences
19 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Lenacapavir, Lenacapavir Tablet and Teropavimab in people with HIV Infections, run by Gilead Sciences at 19 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 19 sites in United States, Australia, Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gilead Clinical Study Information Center (1-833-445-3230 (GILEAD-0), GileadClinicalTrials@gilead.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of Participants With HIV-1 ribonucleic acid (RNA) ≥ 50 Copies/mL at Week 52 as Defined by the United States (US) Food and Drug Administration (FDA) Snapshot Algorithm. (time frame: Week 52). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.